No Data
No Data
Truist Financial Maintains Biomea Fusion(BMEA.US) With Buy Rating
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $11 to $50
Barclays Remains a Hold on Biomea Fusion (BMEA)
Cautious Hold Rating on Biomea Fusion Amid Uncertainties in Drug Efficacy and Financial Outlook
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Biomea Fusion Price Target Lowered to $50 From $60 at Oppenheimer
Unlock the Full List
The Only Way is Up : Give it some time for phase 3
Shroomie The Only Way is Up : it takes like a year for phase 3 lol
Shroomie : it will drop and keep dropping
Shroomie : you're welcome
Shroomie : phase 3 takes a long time. in the meantime, the cash burn is insane, future big dilution coming.. knocking the price lower and lower
View more comments...